Recombinant hepatitis B vaccine (Hansenula Polymorpha, Dalian Hissen BioPharm)

重组乙型肝炎疫苗（艾美汉信）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRecombinant hepatitis B vaccine (Hansenula Polymorpha, Dalian Hissen BioPharm)
Drug Alias NameN/A
ClassificationVaccines > Application > Prophylactic vaccineVaccines > National Immunization Program > Immunization program vaccine(Class I)Vaccines > Development/production technology > Genetically engineered subunit vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsHepatitis B
Global Approved IndicationsHepatitis B
Approved Indications in ChinaHepatitis B
Original Approved Country/TerritoryMainland China
Original Approved Date2004/03/08
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAimei Hissen Vaccine(Dalian) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesAimei Hissen Vaccine(Dalian) Co Ltd
Inactive CompaniesN/A
Active IndicationsHepatitis B
Inactive IndicationsN/A

Other Information

ATC CodeJ07BC01
Related LinksWikipediaDrugBank